Alphabet Raises $80 Billion Through Equity Offerings
Alphabet completed an $80 billion equity package that included a private placement with Berkshire Hathaway and a $40 billion at-the-market offering. Several other technology and semiconductor companies reported separate stock moves tied to earnings or analyst actions.
Alphabet shares fell 2.7 percent in premarket trading after the company raised $80 billion through a package of equity offerings that included a discounted private placement with Berkshire Hathaway and a $40 billion at-the-market offering. Semiconductor stocks advanced as investors shifted positions toward companies viewed as positioned for long-term artificial intelligence growth.
Nvidia rose 1.5 percent, Meta gained 0.5 percent, and Tesla traded flat.
Group shares declined 3 percent after the communications equipment firm reported fourth-quarter results that exceeded forecasts but did not sustain prior momentum. Fulcrum Therapeutics stock dropped 50 percent after the company discontinued its pociredir program for sickle cell disease and began a strategic review.
Generac shares increased 9 percent after the company signed a global supply agreement for backup power generators with a leading hyperscale data center operator. Hewlett Packard Enterprise stock rose 25 percent after the company issued an annual sales outlook that exceeded estimates, citing growth in demand for its servers and networking equipment tied to artificial intelligence.
Intuit shares fell 5 percent after an analyst downgrade to a sell rating, the only negative rating among 32 analysts tracked by Bloomberg. Marvell Technology shares climbed 22 percent after Nvidia’s Jensen Huang referred to the firm as the next trillion-dollar company.
Microchip Technology shares gained 7 percent after the chipmaker reported $302.7 million in revenue from its data center solutions unit for calendar year 2025 and projected about $500 million for the current year. ’s Rob Livingston to succeed Guilherme Lago.
Praxis Precision Medicines shares fell 10 percent after the company said vormatrigine did not meet its primary endpoint in a Phase 2/3 seizure-frequency study.
Transparency
2 independent outlets report the same core facts. This score blends how many outlets corroborate, their editorial tier, and how closely their facts agree — it measures corroboration, not proof.
Story details
Related Stories
U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect
A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.
prnewswire.comFed Chairman Names Two Outside Advisers During Transition
Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.
insidermonkey.comForte Biosciences Accepts Resignation of Director David Veitch
Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…